Details for Patent: 8,349,892

Which drugs does patent 8,349,892 protect, and when does it expire?

Patent 8,349,892 protects ORENITRAM and is included in one NDA.

This patent has eight patent family members in six countries.

Summary for Patent: 8,349,892

Title:	Solid formulations of prostacyclin analogs
Abstract:	Moderate moisture levels, such as greater than 3% but no greater than 7%, may be beneficial for solid formulations of certain prostacyclin analogs. Accordingly, a solid formulation containing a prostacyclin analog may be packaged inside a pharmaceutical packaging with such amount of a desiccant or a drying agent that after the storage the solid formulation may have a moderate level of moisture in it.
Inventor(s):	Phares; Kenneth R. (Hillsborough, NC)
Assignee:	United Therapeutics Corporation (Silver Spring, MD)
Application Number:	12/775,102
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,349,892
Patent Claim Types: see list of patent claims	Formulation; Composition; Use;

Drugs Protected by US Patent 8,349,892

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-001	Dec 20, 2013		RX	Yes	No			Y
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-002	Dec 20, 2013		RX	Yes	No			Y
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-003	Dec 20, 2013		RX	Yes	Yes			Y
United Therap	ORENITRAM	treprostinil diolamine	TABLET, EXTENDED RELEASE;ORAL	203496-004	Dec 20, 2013		RX	Yes	No			Y

International Family Members for US Patent 8,349,892

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2760499
China	102421288
European Patent Office	2427054
Japan	2012526140